Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Purple Biotech (PPBT) Equity Ratio (2016 - 2025)

Purple Biotech has reported Equity Ratio over the past 7 years, most recently at 0.86 for Q4 2022.

  • Quarterly Equity Ratio fell 7.03% to 0.86 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 0.86 through Dec 2022, down 7.03% year-over-year, with the annual reading at 0.86 for FY2022, 7.03% down from the prior year.
  • Equity Ratio was 0.86 for Q4 2022 at Purple Biotech, down from 0.89 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.95 in Q4 2020 and troughed at 0.58 in Q2 2018.
  • The 5-year median for Equity Ratio is 0.88 (2022), against an average of 0.83.
  • Year-over-year, Equity Ratio dropped 29.81% in 2018 and then surged 44.07% in 2021.
  • A 5-year view of Equity Ratio shows it stood at 0.75 in 2018, then decreased by 1.28% to 0.74 in 2019, then grew by 28.99% to 0.95 in 2020, then dropped by 2.54% to 0.93 in 2021, then fell by 7.03% to 0.86 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Equity Ratio are 0.86 (Q4 2022), 0.89 (Q3 2022), and 0.9 (Q2 2022).